Alanine aminotransferase as a risk marker for new-onset metabolic dysfunction-associated fatty liver disease

作者：Di Wang, Bing-Yan Zhou, Lei Xiang, Xuyong Chen, Jiexiong Feng · 发表于：World Journal of Gastroenterology · 年份：2024 · DOI：10.3748/wjg.v30.i25.3132 · 被引用次数：11 · 研究领域：Liver Disease Diagnosis and Treatment、Diet, Metabolism, and Disease、Liver Disease and Transplantation

. Metabolic dysfunction-associated fatty liver disease (MAFLD) is a global public health burden whose incidence has risen concurrently with overweight and obesity. Given its detrimental health impact, early identification of at-risk individuals is crucial. MAFLD diagnosis is based on evidence of hepatic steatosis indicated by liver biopsy, imaging, or blood biomarkers, and one of the following conditions: Overweight/ obesity, type 2 diabetes mellitus, or metabolic dysregulation. However, in large-scale epidemiological studies, liver biopsies are not feasible. The application of techniques such as ultrasonography, computed tomography, magnetic resonance imaging, and magnetic resonance spectroscopy is restricted by their limited sensitivity, low effectiveness, high costs, and need for specialized software. Blood biomarkers offer several advantages, particularly in large-scale epidemiological studies or clinical scenarios where traditional imaging techniques are impractical. Analysis of cumulative effects of excess high-normal blood alanine aminotransferase (ALT) levels of blood ALT levels could facilitate identification of at-risk patients who might not be detected through conventional imaging methods. Accordingly, investigating the utility of blood biomarkers in MAFLD should enhance early detection and monitoring, enabling timely intervention and management and improving patient outcomes.